Business Wire

MA-ACCESS-ADVANCE

9.3.2022 01:02:11 CET | Business Wire | Press release

Share
Access Advance Addresses Düsseldorf Court Ruling, Announces Revised Duplicate Royalty Policy for the HEVC Advance Patent Pool

Access Advance, an independent licensing administrator, today announced that the licensors to its HEVC Advance Patent Pool approved a revised Duplicate Royalty Policy. The revised Policy responds to the Düsseldorf District Court’s December 21, 2021 ruling, which declined to grant an injunction despite finding Vestel Germany GmbH (“Vestel”) liable for damages arising from its infringement of certain HEVC standard essential patents asserted by HEVC Advance licensors.

While Access Advance’s Duplicate Royalty Policy followed (and exceeded) long-standing industry practice, because of the substantial number of overlapping patents in the HEVC Advance Patent Pool and MPEG LA's HEVC patent pool to which Vestel was licensed (as a result of Vestel taking an MPEG LA license in 2018 before a large number of licensors left MPEG LA), the German court found such practice not FRAND. In particular, the court found such practice (1) did not impose on the HEVC Advance Patent Pool a direct legal obligation to Vestel ensuring that a licensor whose patents were licensed in both pools did not receive a duplicate royalty payment, and (2) did not adequately specify to Vestel prior to license execution the methodology each licensor would apply to prevent receipt of such duplicate royalties by licensors.

Importantly, the court once again did not express concerns with any other facet of the HEVC Advance Patent Pool, including its royalty rates. In an earlier set of patent infringement cases brought by several HEVC Advance Patent Pool licensors against MAS Elektronik, this same court expressly confirmed that the HEVC Advance pool license and rates were FRAND. Nothing about the court’s Vestel decision changes or undermines this prior and fundamental finding.

The revised Policy announced today not only resolves the issues identified by the court, but goes a significant step further in allowing licensees under both the HEVC Advance Patent Pool and another HEVC patent pool or joint licensing program that qualify to elect to receive a deduction from the HEVC Advance Patent Pool for the amount of duplicate royalties that would be received by HEVC Advance licensors on account of patents licensed under both the HEVC Advance Patent Pool and the other HEVC patent pool or joint licensing program. Previously, each HEVC Advance licensor could determine from which pool or program a licensee would receive a duplicate royalty deduction.

Details of the revised Duplicate Royalty Policy and the related Duplicate Royalty Adjustment Amendment to the HEVC Advance Patent Portfolio License and Duplicate Royalty Estimate Request can be found at: https://accessadvance.com/licensing-programs/hevc-advance/ .

About Access Advance:

Access Advance LLC (formerly HEVC Advance LLC) is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important standards-based video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers. Access Advance currently manages and administers the HEVC Advance Patent Pool for licensing patents essential to H.265/HEVC technology, and the separate and independent VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. For more information about Access Advance, the HEVC Advance Patent Pool, or the VVC Advance Patent Pool, please visit www.accessadvance.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye